Cargando…
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
A variety of Good Manufacturing Practice (GMP) compliant processes have been reported for production of non-replicating adenovirus vectors, but important challenges remain. Most clinical development of adenovirus vectors now uses simian adenoviruses or rare human serotypes, whereas reported manufact...
Autores principales: | Fedosyuk, Sofiya, Merritt, Thomas, Peralta-Alvarez, Marco Polo, Morris, Susan J, Lam, Ada, Laroudie, Nicolas, Kangokar, Anilkumar, Wright, Daniel, Warimwe, George M, Angell-Manning, Phillip, Ritchie, Adam J, Gilbert, Sarah C, Xenopoulos, Alex, Boumlic, Anissa, Douglas, Alexander D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949866/ https://www.ncbi.nlm.nih.gov/pubmed/31047679 http://dx.doi.org/10.1016/j.vaccine.2019.04.056 |
Ejemplares similares
-
Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
por: Gilbert, Sarah C., et al.
Publicado: (2017) -
A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017) -
Simian adenoviruses as vaccine vectors
por: Morris, Susan J, et al.
Publicado: (2016) -
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021) -
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
por: Jenkin, Daniel, et al.
Publicado: (2022)